- The disease
- Phelan-McDermid syndrome (PMS) is a rare genetic disorder caused by deletion or disruption of the SHANK3 gene on chromosome 22, leading to severe intellectual disability, absent or limited speech, and behavioural features overlapping with autism spectrum disorder. Angelman syndrome (AS) is a separate rare neurogenetic condition caused by loss of function of the UBE3A gene, characterised by severe intellectual disability, impaired speech, seizures, and movement difficulties. Both conditions typically present in early childhood and currently have no approved disease-modifying treatments (per Orphanet disease database). The conditions are classified as ultra-rare, with estimated prevalences in the range of 1 in 20,000 to 1 in 100,000 births (per Orphanet).
- What the asset is trying to do
- NNZ-2591 is an investigational oral peptide therapeutic being developed by Neuren Pharmaceuticals. The specific molecular target of NNZ-2591 is not disclosed in publicly available sources at this time. As a peptide therapeutic, it belongs to a drug class that uses short chains of amino acids to interact with biological pathways; this distinguishes it from small molecule drugs and from gene-based approaches such as antisense oligonucleotides currently in development for related conditions. Further mechanistic detail is pending disclosure by Neuren or publication in a peer-reviewed source.
- What the trial is measuring, and why it matters
- The completed Phase 2 open-label study in Angelman syndrome (NCT05011851, target 17 participants, primary completion May 2024) measured safety, tolerability, and pharmacokinetics (PK) of oral NNZ-2591 (per ClinicalTrials.gov NCT05011851). The lead Phase 3 placebo-controlled study in Phelan-McDermid syndrome (NCT07281079, target 160 participants) is now recruiting; its specific primary endpoint is pending registry update or Neuren disclosure. Safety, tolerability, and PK endpoints are standard early-phase measures used to confirm a drug reaches adequate levels in the body without unacceptable side effects before larger efficacy studies proceed.
- Efficacy benchmarks in this setting
- There are currently no disease-modifying therapies approved by the US Food and Drug Administration (FDA) or European Medicines Agency (EMA) specifically for Phelan-McDermid syndrome or Angelman syndrome (per FDA Orange Book and EMA product database). For Angelman syndrome, antisense oligonucleotide GTX-102 (GeneTx/Ultragenyx) reported clinical activity in an open-label Phase 1/2 study, with details published in the New England Journal of Medicine (Bi et al, NEJM 2024); direct numerical comparison with NNZ-2591 Phase 2 figures is not statistically valid given differences in trial design, patient selection, endpoints, and sample size. For PMS, no pivotal efficacy benchmark from an approved therapy exists against which to compare. Any efficacy figures reported from NNZ-2591's early-phase studies are not statistically comparable to data from other programmes due to the small sample sizes and open-label designs involved.
- Commercial context
- No therapy is currently approved for Phelan-McDermid syndrome or Angelman syndrome in any major market (per FDA Orange Book and EMA product database). Neuren's lead approved asset is DAYBUE (trofinetide), which received FDA approval for Rett syndrome in March 2023 (per FDA approval letter) and is licensed to Acadia Pharmaceuticals for commercialisation in the US; Acadia reported DAYBUE US net sales of US$101 million for Q1 2026, up 20% from Q1 2025 (per Neuren ASX quarterly activities report, 6 May 2026). NNZ-2591 is Neuren's pipeline asset in active Phase 3 development for PMS; its commercial rights and any licensing arrangements for NNZ-2591 are pending company disclosure. Manufacturing and supply chain details for NNZ-2591 are .